High-risk screening and detection of multidrug-resistant tuberculosis in two prefectures of China: a drug susceptibility surveillance-based secondary data analysis

ABSTRACT Background: In China, less than one-fifth of multidrug-resistant tuberculosis (MDR-TB) cases are detected. MDR-TB screening is conducted amongst the following five high-risk groups of TB patients: chronic cases, close contacts of MDR-TB patients, patients with treatment failure, relapsed and returned patients, and smear-positive patients at the end of the third month of initial treatment. Objective: To estimate the possibility of detecting MDR-TB cases if only the high-risk screening strategy is applied in China. Methods: A secondary analysis was applied to the surveillance-based longitudinal data of all sputum smear-positive TB patients in Prefecture E and Prefecture W of China from 2013 to 2015. The population attributable risk (PAR) was estimated using odds ratios for five risk factors/predictors and exposure proportions amongst all MDR-TB cases. Results: A total of 3513 TB patients (2807 from Prefecture E and 706 from Prefecture W) were included. Males accounted for 77.91% (2737/3513) of the patients. The average age was 52.5 ± 20.0 years old. Overall, 40.34% (71/176) of MDR-TB patients were from the five high-risk groups during the three-year study period. The detected proportion of MDR-TB cases using the high-risk screening strategy was significantly higher in Prefecture E than in Prefecture W. The PAR% for all five risk factors/predictors was 43.4% (95% CI: 24.6–61.7%), 49.9% (95% CI: 31.3–67.0%), and 30.3% (95% CI: 12.9–50.1%) in Prefecture E and 36.6% (95% CI: 10.4–64.5%), 13.3% (95% CI: −1.7–39.7%), and −82.5% (95% CI: −117.5–−11.2%) in Prefecture W in 2013, 2014, and 2015, respectively. The PAR% for the five specific risk factors/predictors ranged from 0.4% (95% CI: −0.2–4.8%) to 21.0% (95% CI: 13.1–30.0%) in these two prefectures. Conclusion: In general, a high-risk screening strategy would miss more than half of the MDR-TB patients because they do not belong to the five high-risk groups.

[1]  M. Muniyandi,et al.  Rapid molecular diagnostics for multi-drug resistant tuberculosis in India , 2018, Expert review of anti-infective therapy.

[2]  Y. Pang,et al.  Feasibility of a new model for early detection of patients with multidrug‐resistant tuberculosis in a developed setting of eastern China , 2017, Tropical medicine & international health : TM & IH.

[3]  D. Falzon,et al.  The Global Fund in China: Multidrug-resistant tuberculosis nationwide programmatic scale-up and challenges to transition to full country ownership , 2017, PloS one.

[4]  Qian Gao,et al.  Transmission of multidrug-resistant Mycobacterium tuberculosis in Shanghai, China: a retrospective observational study using whole-genome sequencing and epidemiological investigation. , 2017, The Lancet. Infectious diseases.

[5]  Z. Jia,et al.  Multidrug-resistant tuberculosis (MDR-TB) disease burden in China: a systematic review and spatio-temporal analysis , 2017, BMC Infectious Diseases.

[6]  P. Phillips,et al.  The Impact of a Line Probe Assay Based Diagnostic Algorithm on Time to Treatment Initiation and Treatment Outcomes for Multidrug Resistant TB Patients in Arkhangelsk Region, Russia , 2016, PloS one.

[7]  Zhouqin Lu,et al.  The Prevalence of Drug-Resistant Tuberculosis in Mainland China: An Updated Systematic Review and Meta-Analysis , 2016, PloS one.

[8]  H. Lucas,et al.  Drug-resistant tuberculosis control in China: progress and challenges , 2016, Infectious Diseases of Poverty.

[9]  N. Arinaminpathy,et al.  The Potential Impact of Up-Front Drug Sensitivity Testing on India’s Epidemic of Multi-Drug Resistant Tuberculosis , 2015, PloS one.

[10]  B. Schwartländer,et al.  The Global Fund in China: success beyond the numbers , 2015, The Lancet Global Health.

[11]  Sonya S. Shin,et al.  Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis , 2012, European Respiratory Journal.

[12]  Yu Wang,et al.  National survey of drug-resistant tuberculosis in China. , 2012, The New England journal of medicine.

[13]  Tb Epi-demiological.  The fifth national tuberculosis epidemiological survey in 2010 , 2012 .

[14]  Wei Min Zhang,et al.  Inappropriate tuberculosis treatment regimens in Chinese tuberculosis hospitals. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  M. Andersson,et al.  Risk factors for tuberculosis in Greenland: case-control study. , 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[16]  M. Uplekar,et al.  Engaging hospitals to meet tuberculosis control targets in China: using the Internet as a tool to put policy into practice. , 2010, Bulletin of the World Health Organization.

[17]  You-Ping Li,et al.  Time and spatial distribution of multidrug-resistant tuberculosis among Chinese people, 1981-2006: a systematic review. , 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[18]  K. Floyd,et al.  MDR tuberculosis--critical steps for prevention and control. , 2010, The New England journal of medicine.

[19]  Youping Li,et al.  Risk factors for drug resistance in pulmonary tuberculosis inpatients , 2010, Journal of evidence-based medicine.

[20]  J. Caminero.  Multidrug-resistant tuberculosis: epidemiology, risk factors and case finding. , 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[21]  M. Cheng.  Ministerial meeting agrees plan for tuberculosis control , 2009, The Lancet.

[22]  A. Hayward,et al.  Risk factors for drug resistant tuberculosis in Leicestershire – poor adherence to treatment remains an important cause of resistance , 2003, Epidemiology and Infection.

[23]  Y. Amdekar,et al.  Multidrug resistant tuberculosis. , 1998, Indian pediatrics.